Ramucirumab with paclitaxel or FOLFIRI as second-line treatment in docetaxel-pre-treated patients with metastatic gastric cancer in real-world setting

Ramucirumab with paclitaxel or FOLFIRI as second-line treatment in docetaxel-pre-treated patients with metastatic gastric cancer in real-world setting

Introduction. Ramucirumab (R) with paclitaxel (PTX) is a global standard for second-line (2L) therapy in advanced gastroesophageal adenocarcinoma (GEA). More and more patients (pts) get treated with taxanes in the perioperative or 1st line metastatic setting. For those pts the benefit of a combinati...

Full description

Bibliographic Details
Main Authors: N. S. Besova, Т. А. Titova, А. А. Tryakin, Е. V. Artamonova, Е. S. Obarevich, D. L. Stroyakovskiy, О. Е. Kalinin, I. S. Stilidi
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-06-01
Series:Медицинский совет
Subjects:
ramucirumab
disseminated gastric cancer
irinotecan
folfiri
paclitaxel
docetaxel
second line therapy
Online Access:https://www.med-sovet.pro/jour/article/view/6212

Internet

https://www.med-sovet.pro/jour/article/view/6212

Similar Items